Home › Companies › TRAVERE THERAPEUTICS INC. › 2023-2024

TRAVERE THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and TRAVERE THERAPEUTICS INC.’s Form 8-K, filed May 13, 2024 (Item 5.07 on EDGAR). Page generated October 14, 2026.

13Ballot items
178Asset managers
2,523Fund votes
May 8, 2024Meeting date

Results at a glance

Meeting of May 8, 2024: 13 items on TRAVERE THERAPEUTICS INC.’s Form 8-K, filed May 13, 2024: 10 elected · 3 approved.

Material dissent

Elect Director: John A. Orwin 74% of votes cast Elected Director under 80%
2. Approval of the Company's 2018 Equity Incentive Plan, as amended 62% of votes cast Approved Under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore TRAVERE THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by TRAVERE THERAPEUTICS INC.

These tallies are TRAVERE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 13, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

TRAVERE THERAPEUTICS INC. — official shareholder meeting results, meeting held May 8, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Roy D. Baynes, M.D., Ph.D.	55,967,609	--	--	2,718,503	4,018,872	95%	Elected	—
Elect Director: Suzanne Bruhn, Ph.D.	56,267,040	--	--	2,419,072	4,018,872	96%	Elected	—
Elect Director: Timothy Coughlin	56,365,805	--	--	2,320,307	4,018,872	96%	Elected	—
Elect Director: Eric Dube, Ph.D.	56,468,811	--	--	2,217,301	4,018,872	96%	Elected	—
Elect Director: Gary Lyons	56,039,047	--	--	2,647,065	4,018,872	95%	Elected	—
Elect Director: Jeffrey Meckler	55,841,370	--	--	2,844,742	4,018,872	95%	Elected	—
Elect Director: John A. Orwin	43,710,299	--	--	14,975,813	4,018,872	74%	Elected	—
Elect Director: Sandra Poole	56,051,666	--	--	2,634,446	4,018,872	96%	Elected	—
Elect Director: Ron Squarer	52,269,791	--	--	6,416,321	4,018,872	89%	Elected	—
Elect Director: Ruth Williams-Brinkley	54,959,617	--	--	3,726,495	4,018,872	94%	Elected	—
2. Approval of the Company's 2018 Equity Incentive Plan, as amended	36,375,367	22,098,658	212,086	--	4,018,872	62%	Approved	—
3. Approval, on an advisory basis, of the compensation of the Company's named executive officers	55,789,526	2,854,506	42,079	--	4,018,872	95%	Approved	—
4. Ratification of the Selection of Independent Registered Public Accounting Firm	60,467,774	2,184,775	52,434	--	--	97%	Approved	—

Source: TRAVERE THERAPEUTICS INC., Form 8-K, filed with the SEC on May 13, 2024 — read the filing on EDGAR.

How asset managers voted at the TRAVERE THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 178 asset managers that disclosed a TRAVERE THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Eric Dube, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 56,468,811WITHHELD: 2,217,301

Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Eric Dube

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Eric Dube, Ph.D.”): 56,468,811 for, 2,217,301 withheld, per its Form 8-K filed May 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2025 Annual Meeting of Stockholders.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 24,136,241 for, 24,308 withheld.

FOR

FOR: 24,136,241WITHHOLD: 24,308

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	5,963,914	0	For
State Street	4,172,233	497	For
Delaware/Macquarie	3,582,237	0	For
BlackRock	3,525,131	0	For
Fidelity	1,169,341	0	For
TIAA	728,228	0	For
FINANCIAL INVESTORS TRUST	698,168	0	For
Charles Schwab	555,037	0	For
Principal	470,482	0	For
Columbia Threadneedle	422,969	0	For
Direxion Shares ETF Trust	401,636	0	For
DWS	271,275	0	For
JPMorgan	253,646	0	For
John Hancock	222,488	0	For
Lincoln Financial	215,285	0	For
Voya	184,056	0	For
Equitable	183,429	0	For
ProShares	106,459	0	For
QUANTITATIVE MASTER SERIES LLC	101,946	0	For
SEI	89,010	0	For
Waddell & Reed	68,843	0	For
Dimensional	52,982	0	For
ALPS ETF Trust	52,919	0	For
Russell Investments	52,834	0	For
Brighthouse	28,718	23,811	Mixed

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

2. Elect Director: Gary Lyons

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 56,039,047WITHHELD: 2,647,065

Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Gary Lyons

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Gary Lyons”): 56,039,047 for, 2,647,065 withheld, per its Form 8-K filed May 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2025 Annual Meeting of Stockholders.”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 24,123,293 for, 37,256 withheld.

FOR

FOR: 24,123,293WITHHOLD: 37,256

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	5,963,914	0	For
State Street	4,172,233	497	For
Delaware/Macquarie	3,582,237	0	For
BlackRock	3,525,131	0	For
Fidelity	1,169,341	0	For
TIAA	728,228	0	For
FINANCIAL INVESTORS TRUST	698,168	0	For
Charles Schwab	555,037	0	For
Principal	470,482	0	For
Columbia Threadneedle	422,969	0	For
Direxion Shares ETF Trust	401,636	0	For
DWS	271,275	0	For
JPMorgan	253,646	0	For
John Hancock	222,488	0	For
Lincoln Financial	215,285	0	For
Voya	184,056	0	For
Equitable	183,429	0	For
ProShares	106,459	0	For
QUANTITATIVE MASTER SERIES LLC	101,946	0	For
SEI	89,010	0	For
Waddell & Reed	68,843	0	For
Dimensional	52,982	0	For
ALPS ETF Trust	52,919	0	For
Russell Investments	52,834	0	For
Brighthouse	28,718	23,811	Mixed

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

3. Elect Director: Jeffrey Meckler

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 55,841,370WITHHELD: 2,844,742

Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Jeffrey Meckler

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jeffrey Meckler”): 55,841,370 for, 2,844,742 withheld, per its Form 8-K filed May 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2025 Annual Meeting of Stockholders.”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 24,114,088 for, 46,461 withheld.

FOR

FOR: 24,114,088WITHHOLD: 46,461

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	5,963,914	0	For
State Street	4,171,736	994	For
Delaware/Macquarie	3,582,237	0	For
BlackRock	3,525,131	0	For
Fidelity	1,169,341	0	For
TIAA	728,228	0	For
FINANCIAL INVESTORS TRUST	698,168	0	For
Charles Schwab	555,037	0	For
Principal	470,482	0	For
Columbia Threadneedle	422,969	0	For
Direxion Shares ETF Trust	401,636	0	For
DWS	271,275	0	For
JPMorgan	253,646	0	For
John Hancock	222,488	0	For
Lincoln Financial	215,285	0	For
Voya	184,056	0	For
Equitable	183,429	0	For
ProShares	106,459	0	For
QUANTITATIVE MASTER SERIES LLC	101,946	0	For
SEI	89,010	0	For
Waddell & Reed	68,843	0	For
Dimensional	52,982	0	For
ALPS ETF Trust	52,919	0	For
Russell Investments	52,834	0	For
Brighthouse	28,718	23,811	Mixed

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

4. Elect Director: John A. Orwin

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD

FOR: 43,710,299WITHHELD: 14,975,813

Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: John Orwin

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: John A. Orwin”): 43,710,299 for, 14,975,813 withheld, per its Form 8-K filed May 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2025 Annual Meeting of Stockholders.”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 14,717,890 for, 9,440,305 withheld, 2,354 abstained.

FORWITHHOLD

FOR: 14,717,890ABSTAIN: 2,354WITHHOLD: 9,440,305

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	5,963,914	0	For
State Street	9,205	4,163,525	Withhold
Delaware/Macquarie	0	3,582,237	Withhold
BlackRock	3,525,131	0	For
Fidelity	1,098,040	71,301	Mixed
TIAA	728,228	0	For
FINANCIAL INVESTORS TRUST	698,168	0	For
Charles Schwab	0	555,037	Withhold
Principal	470,224	258	For
Columbia Threadneedle	422,969	0	For
Direxion Shares ETF Trust	401,636	0	For
DWS	0	271,275	Withhold
JPMorgan	253,646	0	For
John Hancock	222,488	0	For
Lincoln Financial	22,267	193,018	Mixed
Voya	0	184,056	Withhold
Equitable	183,429	0	For
ProShares	106,459	0	For
QUANTITATIVE MASTER SERIES LLC	101,946	0	For
SEI	0	89,010	Withhold
Waddell & Reed	0	68,843	Withhold
Dimensional	52,982	0	For
ALPS ETF Trust	52,919	0	For
Russell Investments	52,834	0	For
Brighthouse	28,718	23,811	Mixed

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

5. Elect Director: Ron Squarer

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%

FOR: 52,269,791WITHHELD: 6,416,321

Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Ron Squarer

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ron Squarer”): 52,269,791 for, 6,416,321 withheld, per its Form 8-K filed May 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2025 Annual Meeting of Stockholders.”
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 20,280,843 for, 3,879,706 withheld.

FORWITHHOLD

FOR: 20,280,843WITHHOLD: 3,879,706

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	5,963,914	0	For
State Street	4,172,233	497	For
Delaware/Macquarie	0	3,582,237	Withhold
BlackRock	3,525,131	0	For
Fidelity	1,169,341	0	For
TIAA	728,228	0	For
FINANCIAL INVESTORS TRUST	698,168	0	For
Charles Schwab	555,037	0	For
Principal	470,482	0	For
Columbia Threadneedle	422,969	0	For
Direxion Shares ETF Trust	401,636	0	For
DWS	271,275	0	For
JPMorgan	253,646	0	For
John Hancock	222,488	0	For
Lincoln Financial	85,867	129,418	Mixed
Voya	184,056	0	For
Equitable	183,429	0	For
ProShares	106,459	0	For
QUANTITATIVE MASTER SERIES LLC	101,946	0	For
SEI	89,010	0	For
Waddell & Reed	0	68,843	Withhold
Dimensional	52,982	0	For
ALPS ETF Trust	52,919	0	For
Russell Investments	52,834	0	For
Brighthouse	28,718	23,811	Mixed

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

6. Elect Director: Roy D. Baynes, M.D., Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 55,967,609WITHHELD: 2,718,503

Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Roy Baynes

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Roy D. Baynes, M.D., Ph.D.”): 55,967,609 for, 2,718,503 withheld, per its Form 8-K filed May 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2025 Annual Meeting of Stockholders.”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 24,061,106 for, 99,443 withheld.

FOR

FOR: 24,061,106WITHHOLD: 99,443

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	5,963,914	0	For
State Street	4,171,736	994	For
Delaware/Macquarie	3,582,237	0	For
BlackRock	3,525,131	0	For
Fidelity	1,169,341	0	For
TIAA	728,228	0	For
FINANCIAL INVESTORS TRUST	698,168	0	For
Charles Schwab	555,037	0	For
Principal	470,482	0	For
Columbia Threadneedle	422,969	0	For
Direxion Shares ETF Trust	401,636	0	For
DWS	271,275	0	For
JPMorgan	253,646	0	For
John Hancock	222,488	0	For
Lincoln Financial	215,285	0	For
Voya	184,056	0	For
Equitable	183,429	0	For
ProShares	106,459	0	For
QUANTITATIVE MASTER SERIES LLC	101,946	0	For
SEI	89,010	0	For
Waddell & Reed	68,843	0	For
Dimensional	0	52,982	Withhold
ALPS ETF Trust	52,919	0	For
Russell Investments	52,834	0	For
Brighthouse	28,718	23,811	Mixed

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

7. Elect Director: Ruth Williams-Brinkley

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 54,959,617WITHHELD: 3,726,495

Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Ruth Williams-Brinkley

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ruth Williams-Brinkley”): 54,959,617 for, 3,726,495 withheld, per its Form 8-K filed May 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2025 Annual Meeting of Stockholders.”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 23,365,548 for, 792,647 withheld, 2,354 abstained.

FOR

FOR: 23,365,548ABSTAIN: 2,354WITHHOLD: 792,647

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	5,963,914	0	For
State Street	4,172,233	497	For
Delaware/Macquarie	3,582,237	0	For
BlackRock	3,525,131	0	For
Fidelity	1,169,341	0	For
TIAA	728,228	0	For
FINANCIAL INVESTORS TRUST	698,168	0	For
Charles Schwab	0	555,037	Withhold
Principal	470,224	258	For
Columbia Threadneedle	422,969	0	For
Direxion Shares ETF Trust	401,636	0	For
DWS	271,275	0	For
JPMorgan	253,646	0	For
John Hancock	222,488	0	For
Lincoln Financial	215,285	0	For
Voya	184,056	0	For
Equitable	183,429	0	For
ProShares	106,459	0	For
QUANTITATIVE MASTER SERIES LLC	101,946	0	For
SEI	0	89,010	Withhold
Waddell & Reed	68,843	0	For
Dimensional	52,982	0	For
ALPS ETF Trust	52,919	0	For
Russell Investments	0	52,834	Withhold
Brighthouse	28,718	23,811	Mixed

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

8. Elect Director: Sandra Poole

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 56,051,666WITHHELD: 2,634,446

Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Sandra Poole

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Sandra Poole”): 56,051,666 for, 2,634,446 withheld, per its Form 8-K filed May 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 56 asset managers below reported 24,114,088 for, 46,461 withheld.

FOR

FOR: 24,114,088WITHHOLD: 46,461

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	5,963,914	0	For
State Street	4,171,736	994	For
Delaware/Macquarie	3,582,237	0	For
BlackRock	3,525,131	0	For
Fidelity	1,169,341	0	For
TIAA	728,228	0	For
FINANCIAL INVESTORS TRUST	698,168	0	For
Charles Schwab	555,037	0	For
Principal	470,482	0	For
Columbia Threadneedle	422,969	0	For
Direxion Shares ETF Trust	401,636	0	For
DWS	271,275	0	For
JPMorgan	253,646	0	For
John Hancock	222,488	0	For
Lincoln Financial	215,285	0	For
Voya	184,056	0	For
Equitable	183,429	0	For
ProShares	106,459	0	For
QUANTITATIVE MASTER SERIES LLC	101,946	0	For
SEI	89,010	0	For
Waddell & Reed	68,843	0	For
Dimensional	52,982	0	For
ALPS ETF Trust	52,919	0	For
Russell Investments	52,834	0	For
Brighthouse	28,718	23,811	Mixed

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

9. Elect Director: Suzanne Bruhn, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 56,267,040WITHHELD: 2,419,072

Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Suzanne Bruhn

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Suzanne Bruhn, Ph.D.”): 56,267,040 for, 2,419,072 withheld, per its Form 8-K filed May 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 56 asset managers below reported 24,136,014 for, 24,535 withheld.

FOR

FOR: 24,136,014WITHHOLD: 24,535

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	5,963,914	0	For
State Street	4,172,233	497	For
Delaware/Macquarie	3,582,237	0	For
BlackRock	3,525,131	0	For
Fidelity	1,169,341	0	For
TIAA	728,228	0	For
FINANCIAL INVESTORS TRUST	698,168	0	For
Charles Schwab	555,037	0	For
Principal	470,482	0	For
Columbia Threadneedle	422,969	0	For
Direxion Shares ETF Trust	401,636	0	For
DWS	271,275	0	For
JPMorgan	253,646	0	For
John Hancock	222,488	0	For
Lincoln Financial	215,285	0	For
Voya	184,056	0	For
Equitable	183,429	0	For
ProShares	106,459	0	For
QUANTITATIVE MASTER SERIES LLC	101,946	0	For
SEI	89,010	0	For
Waddell & Reed	68,843	0	For
Dimensional	52,982	0	For
ALPS ETF Trust	52,919	0	For
Russell Investments	52,834	0	For
Brighthouse	28,718	23,811	Mixed

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

10. Elect Director: Timothy Coughlin

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 56,365,805WITHHELD: 2,320,307

Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Timothy Coughlin

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Timothy Coughlin”): 56,365,805 for, 2,320,307 withheld, per its Form 8-K filed May 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 56 asset managers below reported 24,111,101 for, 49,448 withheld.

FOR

FOR: 24,111,101WITHHOLD: 49,448

Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	5,963,914	0	For
State Street	4,172,233	497	For
Delaware/Macquarie	3,582,237	0	For
BlackRock	3,525,131	0	For
Fidelity	1,169,341	0	For
TIAA	728,228	0	For
FINANCIAL INVESTORS TRUST	698,168	0	For
Charles Schwab	555,037	0	For
Principal	470,224	258	For
Columbia Threadneedle	422,969	0	For
Direxion Shares ETF Trust	401,636	0	For
DWS	271,275	0	For
JPMorgan	253,646	0	For
John Hancock	222,488	0	For
Lincoln Financial	215,285	0	For
Voya	184,056	0	For
Equitable	183,429	0	For
ProShares	106,459	0	For
QUANTITATIVE MASTER SERIES LLC	101,946	0	For
SEI	89,010	0	For
Waddell & Reed	68,843	0	For
Dimensional	52,982	0	For
ALPS ETF Trust	52,919	0	For
Russell Investments	52,834	0	For
Brighthouse	28,718	23,811	Mixed

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

11. 2. Approval of the Company's 2018 Equity Incentive Plan, as amended

Official result Fund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

62% Approved · of votes cast

FOR 62%AGAINST

FOR: 36,375,367AGAINST: 22,098,658

Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: TO APPROVE THE COMPANY'S 2018 EQUITY INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY 2,700,000 SHARES.

TRAVERE THERAPEUTICS INC.’s own tally for this item (“2. Approval of the Company's 2018 Equity Incentive Plan, as amended”): 36,375,367 for, 22,098,658 against — passed, per its Form 8-K filed May 13, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Approval of the Company's 2018 Equity Incentive Plan, as amended The Company's stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 2,700,000.”
Support: 62% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 56 asset managers voting on “TO APPROVE THE COMPANY'S 2018 EQUITY INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON ST” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	5,925,614	38,300	0	For
State Street	4,103	4,168,627	0	Against
Delaware/Macquarie	0	3,582,237	0	Against
BlackRock	3,525,131	0	0	For
Fidelity	1,151,341	18,000	0	For
TIAA	728,228	0	0	For
FINANCIAL INVESTORS TRUST	698,168	0	0	For
Charles Schwab	555,037	0	0	For
Principal	462,036	8,446	0	For
Columbia Threadneedle	0	422,969	0	Against
Direxion Shares ETF Trust	0	401,636	0	Against
DWS	0	271,275	0	Against
JPMorgan	253,646	0	0	For
John Hancock	0	222,488	0	Against
Lincoln Financial	22,267	193,018	0	Mixed
Voya	0	184,056	0	Against
Equitable	183,429	0	0	For
ProShares	0	106,459	0	Against
QUANTITATIVE MASTER SERIES LLC	101,946	0	0	For
SEI	89,010	0	0	For
Waddell & Reed	0	68,843	0	Against
Dimensional	0	52,982	0	Against
ALPS ETF Trust	0	52,919	0	Against
Russell Investments	52,834	0	0	For
Brighthouse	0	28,718	23,811	Mixed

Fund voting reports, all 56 managers: 14,008,033 for, 10,081,132 against, 71,384 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 3 asset managers voting on “TO APPROVE THE COMPANY'S 2018 EQUITY INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON ST” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Kynam Capital Management, LP	1,177,370	0	For
Eversept Partners, LP	0	955,618	Against
Palo Alto Investors LP	110,719	0	For

Institutional-manager reports, all 3 managers: 1,288,089 for, 955,618 against.

12. 3. Approval, on an advisory basis, of the compensation of the Company's named executive officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%

FOR: 55,789,526AGAINST: 2,854,506

Details: description as filed, official tally, votes by 176 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

TRAVERE THERAPEUTICS INC.’s own tally for this item (“3. Approval, on an advisory basis, of the compensation of the Company's named executive officers”): 55,789,526 for, 2,854,506 against — passed, per its Form 8-K filed May 13, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports: 56 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	5,963,914	0	0	For
State Street	4,172,730	0	0	For
Delaware/Macquarie	3,582,237	0	0	For
BlackRock	3,525,131	0	0	For
Fidelity	1,169,341	0	0	For
TIAA	728,228	0	0	For
FINANCIAL INVESTORS TRUST	698,168	0	0	For
Charles Schwab	555,037	0	0	For
Principal	470,482	0	0	For
Columbia Threadneedle	422,969	0	0	For
Direxion Shares ETF Trust	401,636	0	0	For
DWS	271,275	0	0	For
JPMorgan	0	253,646	0	Against
John Hancock	222,488	0	0	For
Lincoln Financial	193,018	22,267	0	Mixed
Voya	184,056	0	0	For
Equitable	183,429	0	0	For
ProShares	106,459	0	0	For
QUANTITATIVE MASTER SERIES LLC	101,946	0	0	For
SEI	89,010	0	0	For
Waddell & Reed	68,843	0	0	For
Dimensional	52,982	0	0	For
ALPS ETF Trust	52,919	0	0	For
Russell Investments	52,834	0	0	For
Brighthouse	28,718	0	23,811	Mixed

Fund voting reports, all 56 managers: 23,844,412 for, 292,326 against, 23,811 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 134 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Deep Track Capital, LP	7,370,000	0	For
State Street	5,546,622	0	For
Rock Springs Capital Management LP	3,373,154	0	For
BlackRock	3,003,645	0	For
ARMISTICE CAPITAL, LLC	0	1,756,510	Against
Finepoint Capital LP	1,649,221	0	For
EMERALD MUTUAL FUND ADVISERS TRUST	1,185,668	0	For
Kynam Capital Management, LP	1,177,370	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,120,588	0	For
PICTET ASSET MANAGEMENT SA	1,116,432	0	For
DE Shaw	1,032,528	0	For
Eversept Partners, LP	955,618	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	875,346	0	For
Renaissance	861,585	0	For
EMERALD ADVISERS, LLC	733,970	0	For
Nuveen	730,466	0	For
Two Sigma	661,258	0	For
Charles Schwab	555,037	0	For
Northern Trust	532,739	42	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	500,000	0	For
Rafferty Asset Management, LLC	401,636	0	For
JPMorgan	132	370,410	Against
GW&K Investment Management, LLC	309,638	0	For
Voya	184,056	52,950	Mixed
Knott David M Jr	230,966	0	For

Institutional-manager reports, all 134 managers: 36,940,764 for, 2,568,712 against. Showing the 25 largest; see all in the interactive database.

13. 4. Ratification of the Selection of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%

FOR: 60,467,774AGAINST: 2,184,775

Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.

TRAVERE THERAPEUTICS INC.’s own tally for this item (“4. Ratification of the Selection of Independent Registered Public Accounting Firm”): 60,467,774 for, 2,184,775 against — passed, per its Form 8-K filed May 13, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 24,136,738 for, 23,811 abstained.

FOR

FOR: 24,136,738ABSTAIN: 23,811

Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPA” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	5,963,914	0	For
State Street	4,172,730	0	For
Delaware/Macquarie	3,582,237	0	For
BlackRock	3,525,131	0	For
Fidelity	1,169,341	0	For
TIAA	728,228	0	For
FINANCIAL INVESTORS TRUST	698,168	0	For
Charles Schwab	555,037	0	For
Principal	470,482	0	For
Columbia Threadneedle	422,969	0	For
Direxion Shares ETF Trust	401,636	0	For
DWS	271,275	0	For
JPMorgan	253,646	0	For
John Hancock	222,488	0	For
Lincoln Financial	215,285	0	For
Voya	184,056	0	For
Equitable	183,429	0	For
ProShares	106,459	0	For
QUANTITATIVE MASTER SERIES LLC	101,946	0	For
SEI	89,010	0	For
Waddell & Reed	68,843	0	For
Dimensional	52,982	0	For
ALPS ETF Trust	52,919	0	For
Russell Investments	52,834	0	For
Brighthouse	28,718	23,811	Mixed

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

Largest TRAVERE THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 76,108,829 shares outstanding at the time of that meeting.

Fund voting reports: top TRAVERE THERAPEUTICS INC. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	7.84%
2	State Street	5.48%
3	Delaware/Macquarie	4.71%
4	BlackRock	4.63%
5	Fidelity	1.54%
6	TIAA	0.96%
7	FINANCIAL INVESTORS TRUST	0.92%
8	Charles Schwab	0.73%
9	Principal	0.62%
10	Columbia Threadneedle	0.56%

Institutional-manager reports: top TRAVERE THERAPEUTICS INC. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.”, 2023-2024
#	Asset manager	% of shares outstanding
1	Deep Track Capital, LP	9.68%
2	State Street	7.29%
3	Rock Springs Capital Management LP	4.43%
4	BlackRock	3.95%
5	ARMISTICE CAPITAL, LLC	2.31%
6	Finepoint Capital LP	2.17%
7	EMERALD MUTUAL FUND ADVISERS TRUST	1.56%
8	Kynam Capital Management, LP	1.55%
9	GEODE CAPITAL MANAGEMENT, LLC	1.47%
10	PICTET ASSET MANAGEMENT SA	1.47%

Reported TRAVERE THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

TRAVERE THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
BlackRock	10.64%	13F
Deep Track Capital, LP	9.88%	DEF14A
Armistice Capital, LLC	9.70%	DEF14A
Vanguard Group	8.69%	13F
State Street	8.68%	13F
Macquarie Group Limited	6.24%	DEF14A
Morgan Stanley	5.46%	DEF14A
FMR (Fidelity)	3.80%	13F
Renaissance Technologies	3.76%	13F
Millennium Management	2.89%	13F

Percentages above are of 76,108,829 shares outstanding, as reported by TRAVERE THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from TRAVERE THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At TRAVERE THERAPEUTICS INC.'s shareholder meeting held May 8, 2024, in the 2023-2024 proxy season, 178 asset managers reported how they voted on 13 ballot items in their SEC Form N-PX filings, covering 2,523 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. — TRAVERE THERAPEUTICS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: TRAVERE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 13, 2024.

TRAVERE THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.